Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.creator | Borges, Myrlena Mescouto | - |
Autor(es): dc.creator | Pranchevicius, Maria Cristina da Silva | - |
Autor(es): dc.creator | Noronha, Elza Ferreira | - |
Autor(es): dc.creator | Romero, Gustavo Adolfo Sierra | - |
Autor(es): dc.creator | Carranza Tamayo, César Omar | - |
Data de aceite: dc.date.accessioned | 2021-10-14T17:31:18Z | - |
Data de disponibilização: dc.date.available | 2021-10-14T17:31:18Z | - |
Data de envio: dc.date.issued | 2018-01-04 | - |
Data de envio: dc.date.issued | 2018-01-04 | - |
Data de envio: dc.date.issued | 2017-01 | - |
Fonte completa do material: dc.identifier | http://repositorio.unb.br/handle/10482/30574 | - |
Fonte completa do material: dc.identifier | http://dx.doi.org/10.1590/0037-8682-0455-2016 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/capes/609856 | - |
Descrição: dc.description | Introduction: despite their high toxicity, antimonials and amphotericin B deoxycholate are commonly used for treating visceral leishmaniasis (VL). Few studies showing conflictive data about their efficacy and adverse events in pediatric population are available. This study aimed to evaluate efficacy and safety of amphotericin B deoxycholate vs. that of N-methylglucamine antimoniate in treating pediatric VL in Brazil. Methods: this was a randomized, open-label, 2-arm and controlled pilot clinical trial. Treatment naïve children and adolescents with VL without signs of severe illness were treated with N-methylglucamine antimoniate (20mg/kg/day for 20 days) or amphotericin B deoxycholate (1 mg/kg/day for 14 days). All patients were diagnosed with positive direct examination and/or positive PCR for Leishmania spp. performed in bone marrow samples. The primary efficacy end-point was VL cure determined after 180 days of completion of treatment. The analysis was performed using intention-to-treat (ITT) and per protocol (PP) analyses. Results: in total, 101 volunteers were assessed. Efficacy was similar for both groups. The antimonial (n=51) and amphotericin B groups (n=50) had a cure rate of 94.1% and 100%, and 94% and 97.9% according to ITT and PP analyses, respectively. All patients reported adverse events (AE). Serious AE incidence was similar in both groups. Five individuals were excluded from the study because of severe adverse events. Conclusions: N-methylglucamine antimoniate and amphotericin B deoxycholate have similar efficacy and adverse events rate in pediatric patients with VL. | - |
Formato: dc.format | application/pdf | - |
Idioma: dc.language | en | - |
Publicador: dc.publisher | Sociedade Brasileira de Medicina Tropical - SBMT | - |
Direitos: dc.rights | Acesso Aberto | - |
Direitos: dc.rights | Revista da Sociedade Brasileira de Medicina Tropical - This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0). Fonte: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822017000100067&lng=en&nrm=iso. Acesso em: 22 fev. 2018. | - |
Palavras-chave: dc.subject | Leishmaniose visceral - crianças | - |
Título: dc.title | Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis : an open-label, randomized, and controlled pilot trial in Brazil | - |
Tipo de arquivo: dc.type | livro digital | - |
Aparece nas coleções: | Repositório Institucional – UNB |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: